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Introduction: Management of the immunosuppressed patient with diverticular disease remains contro-
versial.We report the largest series of colon cancer patients undergoing chemotherapy and hospitalized for
acutediverticulitis, to determinewhether recent treatmentwith systemic chemotherapy is associatedwith
increased risk for/increased severity of recurrent diverticulitis. Methods: Retrospective cohort study of
adult patients hospitalized for an initial episode of acute colonic diverticulitis at Memorial Sloan Kettering
Cancer Center, 1988e2004. Outcomes in patients receiving systemic chemotherapy within one month of
admission for diverticulitis (“Chemo”) were compared to outcomes of patients not receiving chemotherapy
within the past month (“No-chemo”). Results: A total 131 patients met inclusion criteria. Chemo patients
did not differ signiﬁcantly from No-chemo group in terms of severity of acute diverticulitis at index
admission (13.2% vs. 4.4%, respectively, p¼ 0.12), resumption of chemotherapy (median 2 months), failure
of non-operative management (13.2% vs 4.4%, respectively, p ¼ 0.12), frequency of recurrence (20.5% vs
18.5%), hospital length of stay (p ¼ 0.08), and likelihood of interval resection (24.0% vs. 16.2%, respectively,
p ¼ 0.39). Chemo patients recurred with more severe disease, were more likely to undergo emergent
surgery (75.0% vs. 23.5%, respectively, p ¼ 0.03), and were more likely to be diverted (100.0% vs. 25.0%,
respectively, p¼ 0.03). Chemopatientswere signiﬁcantlymore likely to incur a postoperative complication
(100% vs 9.1% p< 0.01) following interval resection. Overall mortalitywas signiﬁcantly higher in the Chemo
vs. No-chemo group. Median survival in Chemo patients was 3.4 years; in No-chemo patients, median
survival was not reached at 10 years.Conclusion: Our data do not support routine elective surgery for acute
diverticulitis in patients receiving chemotherapy. Non-operative management in the acute or interval
setting appears preferable whenever possible.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.ment of Surgery , Memorial
l College, 1275 York Avenue,
by Elsevier Ltd. All rights reserved1. Introduction
Colonic diverticular disease affects approximately 25% of the
general population, with an increased prevalence in Western and
industrialized countries, and in older adults [1e6]. Approximately
15% of patients with diverticulosis will eventually develop.
Table 1
Chemotherapeutic agents.
Chemotherapeutic agent n (%)
Doxorubicin 22 (56.4)
Vinca alkaloids 15 (38.5)
Taxol 12 (30.8)
Cyclophosphamide 10 (25.6)
Platinum 10 (25.6)
5-Flourouraicil 4 (10.3)
Gemcitabine 4 (10.3)
Cytoxan 4 (10.3)
Biologics 4 (10.3)
Other 5 (12.8)
Etoposide 3 (7.7)
Percentages do not sum to 100, as 36/39 patients (92.3%) had been
exposed to multiple chemotherapeutic agents at the time of index
hospitalization for diverticulitis.
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colonic inﬂammation that resolves with oral antimicrobial therapy
and dietary modiﬁcation. However, complicated diverticulitis en-
sues in 10% to 15% of cases, leading to perforation and abscess
formation or, in severe instances, secondary fecal peritonitis,
abdominal sepsis, and death [9,10]. Following an initial episode of
diverticulitis managed non-operatively, recurrence rates range
from 13% to 40% [11e16]. When considering an interval segmental
resection, the risk of subsequent recurrence and related compli-
cations must be assessed. Recent data suggests that there is a
relatively low risk of recurrence following a single episode of
diverticulitis, and a low risk of emergent surgical intervention.
Therefore, traditional indications for interval resection have been
relaxed [12,17,18].
Traditionally, the immunosuppressed (IMS) patient has been
considered at increased risk of complicated and recurrent
diverticulitis. Several series report increased morbidity and
mortality from acute diverticulitis in IMS patients, and a high
likelihood that non-operative management (NOM) will fail
[17,19,20]. As a result, some authors have argued for interval
resection following an initial episode of diverticulitis in IMS pa-
tients [4,17,21,22] [23]. However, these studies are limited by
small sample sizes, variable types of immunosuppression, and a
lack of follow-up beyond the initial hospitalization for divertic-
ulitis. In particular, there has been no comparison of risk or
severity of recurrence in cancer patient who are on chemo-
therapy (Chemo) to those who are not (No-chemo). Patients with
cancer have dysregulation of their immune system. When we
discuss the issue of immunity in cancer patients, we should
consider other contributing factors which could inﬂuence results,
such as type of cancer, use of chemotherapeutic agents, stem cell
transplantation, use of corticosteroids and radiation therapy. As a
result, it is very difﬁcult to differentiate between immunosup-
pressed and immunocompetent patients in this diverse popula-
tion. Interval resection decreases the risk of recurrent
diverticulitis; however, major abdominal surgery exposes pa-
tients to morbidity and potential interruption of life-prolonging
chemotherapy. We studied the immediate and long-term out-
comes of patients hospitalized for acute diverticulitis who were
actively receiving systemic chemotherapy, in the hope that these
data may help in clinical decision-making for cancer patients
experiencing an episode of acute diverticulitis. Our primary aim
was to assess whether recent systemic chemotherapy is associ-
ated with an increased severity in presentation of, and morbidity
and mortality from, acute diverticulitis. Our secondary aim was
to assess whether systemic chemotherapy is associated with a
greater likelihood of, and increased severity of, recurrence
[17,19,20,24].
2. Materials and methods
This was a retrospective cohort study of adult (age >18 years)
patients hospitalized with an initial episode of acute colonic
diverticulitis at Memorial Sloan Kettering Cancer Center (MSKCC)
from 1988 to 2004. All patients with a primary episode of acute
diverticulitis who were treated at MSKCC were included in the
study. For the occasional patient who was taken to the operating
room without prior imaging, all episodes were conﬁrmed by im-
aging or operative ﬁndings. Patients were initially identiﬁed using
the codes for diverticulitis (562.11 and 562.13) as speciﬁed in the
International Classiﬁcation for Disease, 9th and 10th revision. The
diagnosis for each patient was subsequently conﬁrmed based on
computed tomography ﬁndings or operative pathology. Patients
with prior episodes of diverticulitis, either at our hospital or else-
where, were excluded from the study. The primary independentvariable was recent exposure to systemic chemotherapy; patients
who received systemic chemotherapy within one month of
admission for diverticulitis (Chemo group) were compared to pa-
tients who had not (No-chemo group). Exposure to chemotherapy
greater than one month prior to the episode of diverticulitis was
considered insufﬁcient to cause immunosuppression [25e27], and
such patients were included in the No-chemo group. We selected
1 month as the cut-off, as that is typically the period during which
we avoid elective cancer surgery; this is due to concerns about
immunosuppression and interference with wound healing. Both
the type and number of chemotherapeutic agents were abstracted,
as was concurrent use of corticosteroids in both the Chemo and No-
chemo groups.
Additional demographic variables included age (years), gender,
and cancer diagnosis (none, lymphoma/leukemia, aerodigestive/
gynecologic/genitourinary, other). Laboratory variables included
admissionwhite blood cell count (K/uL) (WBC), admission absolute
neutrophil count (K/uL) (ANC), neutropenia (ANC < 1.5 K/uL), and
admission serum albumin concentration (g/dL). Variables related to
the index episode of acute diverticulitis included anatomic location
(rectosigmoid vs. other), complicated (phlegmon, abscess, perfo-
ration, obstruction, or ﬁstula) vs. uncomplicated, initial NOM, fail-
ure of NOM, surgical intervention at any time during the index
admission, type of operation (primary anastomosis vs. diversion),
hospital length of stay (LOS) (days), postoperative complications,
and mortality.
Non-operative management was deﬁned as any trial of medical
management in lieu of an immediate operation for diverticulitis.
Although details of NOM varied, the approach generally involved
antimicrobial therapy, intravenous hydration, bowel rest, and
advancement to low-residue diet following resolution of inﬂam-
matory markers (i.e., fever, leukocytosis, abdominal tenderness).
Failure of NOMwas deﬁned as an operation for diverticulitis, at any
time during the index admission, in a patient for whom NOM was
initially attempted. Patients who failed NOM underwent open
exploration. None of the patients in this series received laparo-
scopic wash-out. Diverticulitis was graded with the Hinchey clas-
siﬁcation for the initial as well as the recurrent episode.
Postoperative complications were abstracted according to a stan-
dardized institutional complication-reporting system
[28] (Table 1).
Standardized chemotherapy records were searched to obtain
both the intended and actual date of the next chemotherapy, so that
any interruption and resumption of treatment could be deter-
mined. Medical records were also searched until 2010 for evidence
of recurrence, interval resection, or stoma reversal (where appli-
cable). Recurrent diverticulitis was deﬁned and characterized using
Table 3
Index episode of diverticulitis.
Chemo (n ¼ 39) No chemo (n ¼ 92) p
Sigmoidb 34 (87.2%) 88 (95.7%) 0.08
Complicatedb 24 (61.5%) 44 (47.8%) 0.15
Initial NOMb 30 (76.9%) 71 (77.2%) 0.98
Failure NOMb 5 (13.2%) 4 (4.4%) 0.12
Surgeryb 14 (35.9%) 24 (26.1%) 0.26
Diversionb 10 (71.4%) 19 (79.2%) 0.70
 1 Postoperative complicationb 7 (50.0%) 12 (50.0%) 0.90
LOS (days)a 10.0 (2e44) 8.5 (0e144) 0.08
Mortalityb 2 (5.1%) 4 (4.4%) 0.99
NOM, non-operative management; LOS, length of stay.
a Wilcoxon Signed-Rank test.
b Chi-squared testdunless expected cell counts were <5, in which case Fisher's
Exact Test was used.
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currences were also noted. Complications following both the in-
terval resection and surgery for recurrent diverticulitis were
abstracted, as was the date of last follow-up, presence of a stoma at
last follow-up, and date of mortality.
Statistical analyses were computed using SAS Version 9.1 (SAS
Inc., Carey, NC) and SPSS version 17.0 (SPSS, Inc., Chicago, IL).
Continuous data are expressed as median (range); categorical data
are expressed as No. (%). Medians of continuous data were
compared using the Wilcoxon Signed-Rank test. Proportions of
categorical variables were compared using the Chi-squared
testdunless expected cell counts were <5, in which case Fisher's
Exact Test was used. KaplaneMeier curveswere utilized to estimate
overall survival and time to recurrence of diverticulitis. Time to
recurrence was measured from the date of the index episode of
diverticulitis to the time of ﬁrst recurrence. The Log-rank test was
used to compare the cumulative probability of overall mortality and
recurrence between groups. Statistical signiﬁcance was set at
alpha ¼ 0.05.3. Results
A total of 131 patients met the inclusion criteria; 39 (29.8%) had
received systemic chemotherapy a median of 8 days prior to
admission (range 0e31 days). The chemotherapeutic agents used
are summarized in Table 2. Baseline demographics and admission
laboratory values were compared between the Chemo and No-
chemo groups (Table 3). Age was similar between groups
(p ¼ 0.21), although the Chemo group contained a higher propor-
tion of male patients (64.1% vs. 42.4%, respectively, p ¼ 0.02). Pa-
tients in the Chemo group presented with signiﬁcantly lower WBC
(p < 0.01) and ANC (<0.01) than those in the No-chemo group, and
were more likely to be neutropenic (p < 0.01). Admission serum
albumin concentration did not differ between groups (p ¼ 0.13).
Concurrent use of corticosteroids was signiﬁcantly more common
in the Chemo compared to the No-chemo group (p ¼ 0.03); corti-
costeroids were used either as a component of treatment, or in the
management of chemotherapy-related toxicity.
Data pertaining to the index episode of acute diverticulitis are
summarized in Table 4. In both groups, the site of diverticulitis was
predominantly the rectosigmoid. Chemo patients were not more
likely to present with complicated diverticulitis than No-chemo
patients (61.5% vs. 47.8%, respectively, p ¼ 0.15). There was no dif-
ference between the Chemo and No-chemo groups in the propor-
tion of patients selected for initial NOM (76.9% vs. 77.2%,Table 2
Group demographics.
Chemo (n ¼ 39) No chemo (n ¼ 92) p
Age (years)a 65.9 (35e81.2) 66.3 (25e92) 0.21
Malea 25 (64.1%) 39 (42.4%) 0.02
Cancerb <0.01
None 0 (0%) 28 (30.4%)
Lymphoma/Leukemia 17 (43.6%) 16 (17.4%)
Aerodigestive/GU/GYN 16 (41.0%) 27 (29.4%)
Other 6 (15.4%) 21 (22.8%)
WBC (K/uL)a 7.4 (0.3e30.9) 11.7 (0.9e24.7) <0.01
ANC (K/uL)a 4.5 (0.0e29.9) 9.4 (0.1e20.0) <0.01
Neutropeniab 10 (25.6%) 2 (2.2%) <0.01
Albumin (g/dL)a 3.7 (2.7e4.6) 3.7 (2.2e4.8) 0.13
Corticosteroidsb 15 (38.5%) 19 (20.7%) 0.03
GU, genitourinary; GYN, gynecologic; WBC, white blood cell; ANC, absolute
neutrophil count Neutropenia ¼ ANC < 1.5 K/mL.
a Wilcoxon Signed-Rank test.
b Chi-squared testdunless expected cell counts were <5, in which case Fisher's
Exact Test was used.respectively, p¼ 0.98). Failure of NOMwas uncommon, and did not
differ between the Chemo and No-chemo groups (13.2% vs. 4.4%,
respectively, p ¼ 0.12). Among patients undergoing surgery during
the index admission, the proportion of thosewhowere diverted did
not differ between the Chemo and No-chemo groups (71.4% vs.
79.2%, respectively, p ¼ 0.70). The incidence of any postoperative
complication did not differ between the Chemo and No-chemo
groups (50.0% for each group, p ¼ 0.90). Neither hospital LOS
(p ¼ 0.08) nor mortality (p ¼ 0.99) differed between groups.
Admission for diverticulitis resulted in interruption of chemo-
therapy in 32 of 39 patients (82.1%). Of these 32 patients, 28 (87.5%)
eventually resumed chemotherapy a median of 2.1 months later
(range 0.8e40.4). The remainder (n ¼ 4, 12.5%) did not resume
chemotherapy due to death from cancer progression.
Median follow-up for the sample was 44 months (range 0e241
months). Overall mortality was signiﬁcantly higher for the Chemo
compared to the No-chemo group (Fig. 1). Median survival for the
Chemo group was 3.4 years; median survival for the No-chemo
group had not been reached at 10 years. Patients in the No-
chemo group did not have cancer, had low-risk cancers, or had
cancers that were previously resected without need for systemic
chemotherapy; hence, not all patients in the No-chemo group had
undergone chemotherapy. Among patients who did not undergo
surgery during the index hospitalization (n ¼ 93), the likelihood of
interval resection did not differ between the Chemo and No-chemo
groups (24.0% vs. 16.2%, respectively, p ¼ 0.39). However, the
morbidity of an interval resection was signiﬁcantly higher in the
Chemo compared to the No-chemo group. All patients in the
Chemo group had at least one postoperative complication
following interval resection (n ¼ 6/6, 100%); only 1 patient in the
No-chemo group had a complication (n ¼ 1/11, 9.1%, p < 0.01).
A total of 25 patients (19.0%) developed recurrent diverticulitis:
8 in the Chemo group (20.5%) and 17 in the No-chemo groupTable 4
Episode of recurrent diverticulitis.
Chemo (n ¼ 8) No chemo (n ¼ 17) p
Complicatedb 7 (87.5%) 5 (29.4%) 0.01
Initial NOMb 4 (50.0%) 15 (88.1%) 0.06
Failure NOMb 2 (50.0%) 2 (13.3%) 0.18
Surgeryb 6 (75.0%) 4 (23.5%) 0.03
Diversionb 6 (100.0%) 1 (25.0%) 0.03
 1 Postoperative complicationb 4 (66.7%) 2 (50.0%) 0.99
LOS (days)a 17 (9e60) 6 (0e40) 0.01
Mortalityb 1 (12.5%) 0 (0.0%) 0.32
NOM, non-operative management; LOS, length of stay.
a Wilcoxon Signed-Rank test.
b Chi-squared testdunless expected cell counts were <5, in which case Fisher's
Exact Test was used.
Fig. 1. Overall mortality.
Complications.
Grade of complication Management and result
1 Requiring oral medication
2 Requiring intravenous treatment
3 Requiring surgical or image-guided intervention
4 Resulting in permanent disability
5 Death
Table 5
Postoperative complications.
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tween groups (Fig. 2). Outcomes of the episode of recurrent
diverticulitis are shown in Table 4. The likelihood of recurrence of
complicated diverticulitis was signiﬁcantly increased in the Chemo
group compared to the No-chemo group (87.5% vs. 29.4%, respec-
tively, p ¼ 0.01). A trend towards decreased likelihood of NOM for
recurrent diverticulitis was observed for the Chemo group
compared to the No-chemo group, although this did not reach
statistical signiﬁcance (50.0% vs. 88.1%, respectively, p ¼ 0.06).
There was no signiﬁcant difference in the likelihood of failure of
NOM between groups, although this was a rare event (n ¼ 2 for
each group). However, Chemo patients were signiﬁcantly more
likely than No-chemo patients to require emergent surgery during
hospitalization for recurrent diverticulitis (75.0% vs. 23.5%,
respectively, p ¼ 0.03), and were more likely to be diverted (100.0%
vs. 25.0%, respectively, p ¼ 0.03). Differences in perioperative
morbidity (p ¼ 0.99) and mortality (p ¼ 0.32) did not reach sta-
tistical signiﬁcance.Fig. 2. Recurrent diverticulitis.Speciﬁc postoperative complications following emergent sur-
gery for the initial episode of diverticulitis, elective interval resec-
tion, and emergent surgery for recurrent diverticulitis, are
summarized in Table 5. Multiple recurrences were rare (n ¼ 8/131,
6.1%), and were not more common in the Chemo compared to the
No-chemo group (3.1% vs. 7.6%, p ¼ 0.43). Chemo patients were not
more likely to have a stoma at last follow-up (28.2% vs. 15.2%,
respectively, p ¼ 0.08).
4. Discussion
The guidelines put forth in 2014 by the American Society of
Colon and Rectal Surgeons (ASCRS) recommend that surgeons
maintain a low threshold when considering operative intervention
as deﬁnitive treatment, during the ﬁrst hospitalization for acute
diverticulitis, in immunosuppressed patients with chronic renal
failure or collagen vascular disease. That is because these patients
are at greater risk of recurrent complicated diverticulitis, requiring
emergency surgery. Furthermore, most authors recommend inter-
val resection following a single episode of diverticulitis in IMS pa-
tients Despite these recommendations, there is no data comparing
initial and long-term outcomes of acute diverticulitis in cancer
patients who are on chemotherapy to patients who are not
[4,21,22]. In this study, the Chemo group did not differ signiﬁcantly
from the No-chemo group in terms of severity of index episode of
acute diverticulitis, time to resumption of chemotherapy, failure of
NOM, or frequency of recurrence. Chemo patients recurred with
more severe disease, were more likely to undergo emergent sur-
gery, and were more likely to be diverted; however, perioperative
morbidity and mortality were not increased relative to No-chemoInitial episode Interval
resection
First recurrence
Chemo No
chemo
Chemo No
chemo
Chemo No
chemo
Patients undergoing
surgery
14 24 6 11 6 4
Patients with 1
complication
7 12 6 1 4 2
Surgical site infection 2 3 e e 2 e
Intra-abdominal abscess 2 4 e e 1 1
Pneumonia 1 2 2 e 2 e
Urinary tract infection e e 1 e 1 2
Sepsis 2 2 e e 1 e
Wound dehiscence 1 e e e e e
Ileus e 1 1 1 e e
Venous
thromboembolism
e 1 1 e 1 e
Colovesical ﬁstula e 1 e e e e
Intra-abdominal
hemorrhage
e e 1 e e e
Gastrointestinal
hemorrhage
e 1 1 e e e
Atrial ﬁbrillation e 1 2 e 1 e
Total complications do not sum to the total number of patients with 1 complica-
tion, as some patients had more than one complication.
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to incur a postoperative complication following interval resection.
These data argue against routine surgical intervention in Chemo
patients with diverticulitis, in both the acute and interval settings.
Prior data addressing outcomes in IMS patients with divertic-
ulitis are sparse. Perkins et al. reviewed 86 patients admitted with
diverticulitis from 1980 to 1983; 10 patients were immunocom-
promised, 3 of whom had recently received chemotherapy [19]. All
of the IMS patients failed NOM, compared with only 24% of the
immunocompetent patients. Both morbidity and mortality were
increased in the IMS group, although statistical signiﬁcance was
not reported. Tyau et al. reported on 209 patients with divertic-
ulitis treated at a single institution from 1984 to 1989 [20]. Forty
patients (19%) were immunocompromised, 6 of whom had
recently undergone chemotherapy. Again, a higher likelihood of
failure of NOM was observed in the IMS compared to the Non-IMS
group (58% vs. 32%, respectively, p < 0.05), as were higher rates of
postoperative morbidity (65% vs. 23.6%, p < 0.05) and mortality
(39.1% vs. 1.8%). Chapman et al. described a similar association
between IMS and morbidity and mortality from complicated
diverticulitis [17].
The results of our study differ from these reports in several
ways. In the current series, NOM was attempted in a majority of
cases and rarely failed, regardless of exposure to chemotherapy.
Furthermore, postoperative morbidity and mortality were lower in
the Chemo group than has been reported in previous studies. These
disparities may reﬂect either a general improvement in NOM of
patients with diverticulitis over time, or a healthier cohort of
Chemo patients. The overall incidence of recurrent diverticulitis in
our series (19.5%) was also lower than in many previous studies
[11,13,14]. Finally, the relatively low incidence of interval resection
in the Chemo group (24.0%) suggests a disparity between existing
recommendations and current practice.
Our ﬁndings indicate that the increased severity of recurrent
disease does not justify mandatory interval resection following a
single episode of diverticulitis. However, while these data may be
used to inform decision-making, clinical judgment remains para-
mount inmanaging the individual patient with diverticular disease.
Our study is limited by the possibility of a Type II error, secondary
to small sample size. In particular, a larger sample may have
revealed signiﬁcant differences in the likelihood of either compli-
cated diverticulitis or failure of NOM between the Chemo and No-
chemo groups for the index admission. In both groups, however,
failure of NOM was rare. An additional limitation common to
retrospective studies involves confounding; the Chemo and No-
chemo groups likely differed systematically in ways other than
exposure to chemotherapy. For example, approximately one-third
of patients in the No-chemo group had no history of malignancy.
The signiﬁcantly higher overall mortality observed in the Chemo
group underscores the possibility of such confounding. However,
this observation should be incorporated into the management of
chemotherapy patients with diverticulitis, and should inform any
decision to proceed with interval resection. Another difference
involved the greater likelihood of corticosteroid use in the Chemo
group versus the No-chemo group. Although corticosteroid use
may have exerted an independent immunosuppressive effect,
many of the patients in the Chemo group received only a single
dose of steroids during chemotherapy, for anti-emetic purposes.
Unfortunately, the small overall sample size precluded subgroup
analysis of patients who did not receive steroids. However, the
equivalent severity of disease observed in the Chemo and No-
chemo groups during the index admission argues against a sub-
stantial degree of confounding by steroid use.
Caution should be exercised in extrapolating our results to other
groups of IMS patients (e.g., transplant patients). Biondo et al.concluded that IMS patients with diverticulitis who were treated
successfully by medical management need not be advised to un-
dergo elective sigmoidectomy more often than Non-IMS patients
(16). We arrived at the same conclusion, based on our experience
with a cancer patient population.
Use of recent exposure to chemotherapy as the primary pre-
dictive variable likely captured a relatively broad range of IMS pa-
tients. It is possible that additional reﬁning of the sample (e.g., to
patients who had either received chemotherapy within a shorter
interval prior to presentation, or had documented neutropenia at
presentation), may have increased the ability to detect a deleterious
effect of chemotherapy. However, such a limitation would preclude
a meaningful statistical analysis. Finally, our comparator group
consisted predominantly of patients with malignancy–a comor-
bidity that may cause immunosuppression independent of
chemotherapy. It is possible that chemotherapy patients with
diverticulitis may fare worse compared to the general population.
However, this particular control group was chosen in order to
minimize additional confounding.
5. Conclusions
Our report comprises the largest series of chemotherapy pa-
tients hospitalized for acute diverticulitis. In comparison to patients
not exposed to chemotherapy, chemotherapy patients did not
present with more severe disease and were not more likely to fail
NOMduring the index hospitalization. Chemotherapywas resumed
in a majority of patients following the episode of diverticulitis. In-
terval resection was associated with a signiﬁcantly increased
morbidity in chemotherapy patients. Finally, the likelihood of
recurrence was not increased in the Chemo group, although
recurrent disease was more severe in these patients. These data do
not support application of the current recommendationsdfor
routine elective surgical management of IMS patients with acute
diverticulitis, including interval resection following a single epi-
sodedto those receiving chemotherapy. NOM, whether in the
acute or interval setting, appears preferable in this population
whenever possible. In practice, care must be individualized
regardless of exposure to chemotherapy. Continued research is
needed in order to reﬁne an evidence-based approach to the
management of IMS patients with diverticular disease.
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